AbbVie Inc (ABBV)vsGeneDx Holdings Corp. (WGS)
ABBV
AbbVie Inc
$245.87
+0.89%
HEALTHCARE · Cap: $430.82B
WGS
GeneDx Holdings Corp.
$77.08
+10.76%
HEALTHCARE · Cap: $1.93B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 14445% more annual revenue ($64.39B vs $442.68M). ABBV leads profitability with a 9.8% profit margin vs -17.6%. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
WGS
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-63.1%
Fair Value
$150.90
Current Price
$245.87
$94.97 premium
Intrinsic value data unavailable for WGS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 39.6%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
17.4% revenue growth
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Trading at 9.0x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -30.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.41 suggests the stock is reasonably priced for its growth.
Bull Case : WGS
The strongest argument for WGS centers on Revenue Growth. Revenue growth of 17.4% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 68.9x leaves little room for execution misses.
Bear Case : WGS
The primary concerns for WGS are Price/Book, EPS Growth, Market Cap.
Key Dynamics to Monitor
ABBV profiles as a value stock while WGS is a growth play — different risk/reward profiles.
WGS carries more volatility with a beta of 1.91 — expect wider price swings.
WGS is growing revenue faster at 17.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 27/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
GeneDx Holdings Corp.
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Sema4 Holdings Corp. The company is headquartered in Stamford, Connecticut.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?